About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Eradication of Barrett's Esophagus After Endoluminal Therapies Have a High Success Rate

by Bidita Debnath on February 18, 2013 at 8:58 PM
Font : A-A+

 Eradication of Barrett's Esophagus After Endoluminal Therapies Have a High Success Rate

Barrett's esophagus (BE) is a precancerous condition with a known risk of progressing to cancer, especially when high-grade dysplasia (HGD, abnormal cells) is observed.

A new study from researchers at the Hospital of the University of Pennsylvania reports that endoluminal (endoscopic) therapies, combining resection and ablation techniques, for patients with Barrett's esophagus and high-grade dysplasia or early mucosal cancer have a high success rate, with durable results and a low risk of complications. The researchers noted that endoscopic surveillance after successful eradication is required. The study appears in the February issue of GIE: Gastrointestinal Endoscopy, the monthly peer-reviewed scientific journal of the American Society for Gastrointestinal Endoscopy (ASGE).

Advertisement

Esophagectomy has been the standard treatment for BE with HGD or early mucosal cancer (intramucosal carcinoma). Endoluminal therapy is an alternative to operative resection in selected patients with decreased morbidity and equivalent long-term results to surgery.

"Endoluminal therapy has not been broadly applied, and there is limited long-term follow-up. Moreover, endoluminal therapy techniques have evolved over time, challenging assessments of long-term efficacy and effectiveness," said study lead author Gregory G. Ginsberg, MD, FASGE, Hospital of the University of Pennsylvania and past president of the American Society for Gastrointestinal Endoscopy. "We sought to assess the efficacy, safety, and durability of an aggressive, endoscopic, multiple-mode approach of complete eradication of intestinal metaplasia (abnormal cells) in patients with HGD and/or intramucosal carcinoma. We found that multiple-mode endoluminal therapy, combining resection and ablation techniques, for Barrett's esophagus with high-grade dysplasia or early cancer with intention to complete eradication of all intestinal metaplasia was successful, with low observed recurrence of dysplasia or cancer. However, recurrence of intestinal metaplasia occurs in one-third of cases, therefore persistent vigilant surveillance is required."
Advertisement

Endoluminal Therapies Endoscopic therapy may include removal of Barrett's with dysplasia using endoscopic mucosal resection, which removes abnormal tissue in the esophagus without damaging the rest of the esophagus.Endoscopic ablation of Barrett's tissue can be done with either radiofrequency ablation, which destroys and kills cells by heating them, or cryotherapy, which destroys cells by freezing them. After either treatment, the esophagus grows back a normal healthy lining.

Methods Endoluminal therapy is an option for selected patients with Barrett's esophagus and high-gradedysplasia or early cancer. In this study, researchers sought to assess long-term outcomes of patients treated with endoluminal therapy with the goal of complete eradication of all dysplasia and intestinal metaplasia. This was a retrospective cohort study of selected patients referred with dysplastic Barrett's esophagus at the Hospital of the University of Pennsylvania between January 1998 and December 2009. Patients received endoluminal therapy combining resection and photodynamic therapy, radiofrequency ablation, and/or argon plasma coagulation treatment that was individualized based on patient and lesion characteristics, technique evolution and interval response. Complete eradication of dysplasia, all intestinal metaplasia, and recurrences was assessed.

Results A total of 166 patients were treated and had at least one year of follow-up. Complete elimination of neoplasia (abnormal cells) was achieved in 157 patients (95 percent) and complete elimination of intestinal metaplasia was achieved in 137 patients (83 percent). After therapy, patients were followed for 33 (range 18-58) months. Among patients who achieved complete elimination of intestinal metaplasia, subsequent recurrent intestinal metaplasia was detected in 48 (35 percent) and dysplasia in 12 (9 percent).

Among those who achieved only complete elimination of dysplasia, recurrent dysplasia was detected in six of 19 patients (32 percent). Statistical analysis showed that multifocal dysplasia and patient's age were risk factors for dysplasia and carcinoma recurrence, and complete elimination of intestinal metaplasia was a protective factor. Retreatment achieved remission in 90 percent of cases. Forty-two patients (23.9 percent) had complications, including 21 with stricture (11.9 percent) and one treatment-related death. Most adverse events were minor and responded to endoscopic or supportive therapy.

The researchers concluded that multiple-mode endoluminal therapy, combining resection and ablation techniques, for patients with BE and HGD and/or early mucosal cancer, with the intention of achieving complete eradication of all intestinal metaplasia can achieve a high success rate with durable results and low risk of morbidity. However, endoluminal therapy typically requires multiple treatment sessions over many months, life-long proton-pump inhibitor therapy, and a commitment to endoscopic surveillance after successful eradication. Although the risk of dysplasia or cancer recurrence is low, it is increased when multifocal dysplasia is detected before and during treatment. Additionally, intestinal metaplasia recurrence is detected in one-third of successfully treated patients, and it can occur long after initial eradication was achieved. Therefore, endoscopic surveillance even after successful eradication is required.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Health Benefits of Sea Buckthorn
Contraceptive Pills in Polycystic Ovary Syndrome (PCOS) Curtail Type 2 Diabetes Risk
Mushroom May Help Cut Down the Odds of Developing Depression
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Tongue Abnormalities Difficulty Swallowing Symptom Evaluation Esophageal Disorders Esophageal Cancer Achalasia Eosinophilic Esophagitis (EoE) 

Recommended Reading
New Strategy for Interfering With a Potent Cancer-causing Gene Identified
In 70% of patients, Acute myeloid leukemia (AML) is an aggressive blood cancer that is currently ......
Mussels Hold Key to Surgery, Cancer Treatment
Materials that mimic the mussels' sticky proteins have been created by scientists. The synthetic ......
Chemotherapy May Raise Leukemia Risk in Cancer Patients
Chemotherapy may increase a patient's risk of developing therapy-related acute myeloid leukemia, a ....
Copper Depletion Therapy Keeps Breast Cancer at Bay
The median survival for metastatic triple-negative breast cancer patients is historically nine ......
Achalasia
In achalasia food fails to pass into the stomach due to constriction of the lower esophageal sphinct...
Difficulty Swallowing Symptom Evaluation
Difficulty with swallowing or dysphagia is a problem, which if left untreated, could cause malnutrit...
Eosinophilic Esophagitis (EoE)
Eosinophilic esophagitis (EoE) / allergic esophagitis / esophagus allergy is an allergic inflammator...
Esophageal Cancer
Esophageal cancer refers to malignancy of the food pipe which connects the throat to the stomach. It...
Esophageal Disorders
Esophagus is the tubular structure that carries food, liquids and saliva from mouth to the stomach. ...
Tongue Abnormalities
Tongue is the only muscle that is attached to only one end. The abnormalities of the tongue include ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use